Cuevas Almanzora

Research and Markets ( http://www.researchandmarkets.com/research/af1a4c/molecular_diagnost : http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.researchandmarkets.com%2Fresearch%2Faf1a4c%2Fmolecular_diagnost&esheet=6486182&lan=en-US&anchor=http%3A%2F%2Fwww.researchandmarkets.com%2Fresearch%2Faf1a4c%2Fmolecular_diagnost&index=1&md5=a86585237bb4e3ae28db39c11033d9fd ) has announced the addition of the ” Molecular Diagnostics: Market Segmentation and Opportunities : http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.researchandmarkets.com%2Fresearch%2Faf1a4c%2Fmolecular_diagnost&esheet=6486182&lan=en-US&anchor=Molecular+Diagnostics%3A+Market+Segmentation+and+Opportunities&index=2&md5=ed57a3b0b290982c62beb61e305f841b ” report to their offering. Molecular diagnostics (MDx) is a class of diagnostic tests that identify nucleic acids such as DNA. These nucleic acids can be genetic material of foreign organisms (e.g., HIV infection) or genetic markers of individual patients (e.g., Her-2 overexpression in breast cancer). In recent years, MDx has experienced fast growth, given these tests high sensitivity, fast turnaround times and relatively low-cost compared to culturebased or immune-based techniques

SEATTLE, WA — (Marketwire) — 09/24/10 — Pacific Biomarkers, Inc. (OTCBB: PBMC), which provides specialty laboratory services to support pharmaceutical, biotechnology and laboratory diagnostic companies in the conduct of human clinical research, for use in their drug and diagnostic product development efforts, today released its financial results for FY2010. For the twelve months ended June 30, 2010 (FY2010), revenue decreased 11% to $9,664,861, compared with record revenues of $10,881,107 in FY2009.

STOCKHOLM, SWEDEN — (Marketwire) — 08/29/10 — Portola Pharmaceuticals, Inc. today announced additional pharmacodynamic data from a pre-specified analysis of EXPLORE-Xa, a Phase 2 dose-finding study of betrixaban, an investigational oral direct Factor Xa inhibitor. During a poster session at the European Society of Cardiology (ESC) Congress in Stockholm, Dr. Stuart Connolly, EXPLORE-Xa principal investigator and director, Division of Cardiology, McMaster University, Hamilton, Ontario, presented data from the analysis of three separate pharmacodynamic markers for anticoagulation (anti-Factor Xa units, thrombin generation and D-dimer) in plasma samples collected from patients enrolled in the EXPLORE-Xa clinical trial. The results showed a

Research and Markets ( http://www.researchandmarkets.com/research/0ed35f/biomarkers_applic : http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.researchandmarkets.com%2Fresearch%2F0ed35f%2Fbiomarkers_applic&esheet=6409052&lan=en-US&anchor=http%3A%2F%2Fwww.researchandmarkets.com%2Fresearch%2F0ed35f%2Fbiomarkers_applic&index=1&md5=a9a1501bd535e35f5424b0d16010dc8b ) has announced the addition of the ” Biomarkers. Applications and Trends : http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.researchandmarkets.com%2Fresearch%2F0ed35f%2Fbiomarkers_applic&esheet=6409052&lan=en-US&anchor=Biomarkers%3A+Applications+and+Trends&index=2&md5=9a4da3b0292a4dec63d5326b9565ca91 ” report to their offering. While Biomarker research is still in its infancy, great strides have been made in the discovery and utilisation of biomarkers in the development of targeted cancer therapeutics and companion diagnostics. Furthermore, there are still significant opportunities in other disease areas to improve productivity by identifying the most suitable developmental candidates earlier during the R&D process. Stakeholder engagement is critical.